Komori
Share Issuance and Disposal4598Delta-Fly Pharma,Inc.Pharmaceuticals

Notice Regarding the Monthly Exercise Status of the 11th Series of Stock Acquisition Rights (Stock Acquisition Rights with Provisions for Adjustment of the Exercise Price)

During February 2026, 8,151 of the 11th Series Stock Acquisition Rights were exercised, and 815,100 new shares were issued. The number of rights remaining unexercised at month-end was 21,849.

Worth reading
66In focus
Scored from 1 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
815100
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Report on the monthly exercise status of stock acquisition rights with exercise price adjustment clauses

Who receives how much

対象月間の交付株式数:815,100株(新株式815,100株、移転自己株式0株)

Macquarie Bank Limited (the allottee of the previously issued 11th Stock Acquisition Rights)

The lower thin line represents the existing number of shares to which these shares will be added.

Terms of the stock acquisition rights
Exercise price
対象月の行使価額:246円、201円、200円。修正条項の詳細および下限:Not disclosed
Number of Stock Acquisition Rights
発行総数:30,000個(8,151個行使、発行総数の27.17%)。対象月末の未行使残:21,849個
Procedures under the Corporate Code of Conduct
Report on compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financing
2026年2月2日発行:第11回新株予約権(行使価額修正条項付新株予約権)。金額:Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalReport on the monthly exercise status of stock acquisition rights with exercise price adjustment clauses
Number of shares to be issued or disposed of対象月間の交付株式数:815,100株(新株式815,100株、移転自己株式0株)
Intended allotteeMacquarie Bank Limited (the allottee of the previously issued 11th Stock Acquisition Rights)
Total number of issued shares12,159,900株(対象月の前月末時点、うち自己株式198株) → Not disclosed
Exercise price対象月の行使価額:246円、201円、200円。修正条項の詳細および下限:Not disclosed
Number of Stock Acquisition Rights発行総数:30,000個(8,151個行使、発行総数の27.17%)。対象月末の未行使残:21,849個
Procedures under the Corporate Code of ConductReport on compliance with the exercise restrictions under Article 434 of the Tokyo Stock Exchange's Securities Listing Regulations and the Japan Securities Dealers Association's Rules Concerning the Handling of Third-Party Allotments and Other Matters
Most recent equity financing2026年2月2日発行:第11回新株予約権(行使価額修正条項付新株予約権)。金額:Not disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyDilution RateBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

会社は、2026年2月の月間行使状況を報告するためとしている。

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Monthly Exercise Status of the 11th Series of Stock Acquisition Rights (Stock Acquisition Rights with Provisions for Adjustment of the Exercise Price) | Delta-Fly Pharma,Inc. (4598) timely disclosure | Komori